T1期膀胱癌再次电切具有肿瘤学生存获益:一项比较有效性研究
该研究基于加拿大安大略省2001至2015年人群数据,纳入7666例初诊T1期膀胱癌患者,比较再次电切与未再次电切的生存结局。2162例(28.7%)接受再次电切,中位时间45天。未调整分析显示再次电切与更低的全因死亡(HR 0.68)和膀胱癌特异死亡(HR 0.66)相关;多因素调整后全因死亡获益仍显著(HR 0.88),肿瘤特异生存获益边缘不显著(HR 0.87,P=0.08)。
要点
- T1期膀胱癌再次电切与更低的全因死亡风险独立相关(调整后HR 0.88)。
- 肿瘤特异生存获益在调整混杂后边缘不显著(HR 0.87,P=0.08)。
- 再次电切中位时间为45天,多在初次电切后2-10周内完成。
核心结论
- 在真实世界人群中,T1期膀胱癌再次电切与更低的全因死亡风险显著相关,支持其肿瘤学获益。
研究设计与样本
- 基于病理报告链接健康行政数据的回顾性全省人群观察性队列研究。
- 纳入2001年1月至2015年12月安大略省初诊T1期膀胱癌患者7666例。
- 通过账单记录判定是否在初次电切后2-10周内接受再次电切。
- 采用Cox比例风险回归分析再次电切对生存结局的时间依赖性效应,并调整患者和术者层面混杂变量。
主要发现
- 7666例患者中2162例(28.7%)接受再次电切,中位(四分位距)时间为45(35-56)天。
- 未调整分析中,再次电切与更低的全因死亡风险相关(HR 0.68,95%CI 0.63-0.74,P<0.001)。
- 未调整分析中,再次电切与更低的膀胱癌特异死亡风险相关(HR 0.66,95%CI 0.57-0.76,P<0.001)。
- 调整所有假定混杂变量后,再次电切仍与更低的全因死亡风险显著相关(HR 0.88,95%CI 0.81-0.95,P<0.001)。
- 调整后,再次电切与肿瘤特异生存的关联边缘不显著(HR 0.87,95%CI 0.75-1.02,P=0.08)。
关键数值与推荐
- 推荐初诊T1期膀胱癌患者在初次电切后2-6周内接受第二次经尿道电切(即再次电切)。
临床怎么用
- 对于初诊T1期膀胱癌,应考虑在初次电切后2-6周内安排再次电切以改善生存结局。
- 再次电切的决策需结合患者个体情况和既往证据,平衡诊断、治疗和预后获益。
局限性
- 既往关于再次电切生存终点的研究稀少、结论矛盾且常受各种偏倚影响。
- 本研究为观察性设计,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To quantify the real-world survival benefit of re-resection vs no re-resection in patients diagnosed with T1 bladder cancer (BC) at the population level. PATIENTS AND METHODS: Retrospective population-wide observational cohort study based on pathology reports linked to health administrative data. We identified patients who were diagnosed with T1 BC in the province of Ontario (01/2001-12/2015) and used billing claims to ascertain whether they received re-resection within 2-10 weeks. The time-dependent effect of re-resection on survival outcomes was modelled by Cox proportional hazards regression (unadjusted and adjusted for numerous assumed patient- and surgeon-level confounding variables). Effect measures were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: We identified 7666 patients of which 2162 (28.7%) underwent re-resection after a median (interquartile range) time of 45 (35-56) days. Patients who received re-resection were less likely to die from any causes (HR 0.68, 95% CI 0.63-0.74, P < 0.001) and from BC (HR 0.66, 95% CI 0.57-0.76, P < 0.001) during any time of follow-up. After adjusting for all assumed confounding variables, re-resection was still significantly associated with a lower overall mortality (HR 0.88, 95% CI 0.81-0.95, P < 0.001), while the association with cancer-specific survival marginally lost its statistical significance (HR 0.87, 95% CI 0.75-1.02, P = 0.08). CONCLUSIONS: A second transurethral resection within 2-6 weeks after the initial resection (i.e. re-resection) is recommended for patients diagnosed with primary T1 BC as prior studies suggest therapeutic, diagnostic, and prognostic benefits. However, results on survival endpoints are sparse, conflicting, and often affected by various biases. To the best of our knowledge, the present population-wide study represents the largest cohort of patients diagnosed with T1 BC and provides real-world evidence supporting the utilisation of re-resection in this group of patients.
引用
- Wettstein MS, Baxter NN, Sutradhar R, et al. Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study. BJU Int. 2021. PMID: 34674366. doi:10.1111/bju.15622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。